Comparative Pharmacology
Head-to-head clinical analysis: ARANELLE versus PIRMELLA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANELLE versus PIRMELLA 1 35.
ARANELLE vs PIRMELLA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Additionally, causes cervical mucus thickening and endometrial atrophy, reducing sperm penetration and implantation.
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet orally once daily for 21 days, followed by 7 placebo tablets during the withdrawal bleed.
None Documented
None Documented
Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing
Terminal half-life 24–30 hours for ethinyl estradiol; 13–18 hours for norethindrone. Steady state reached after 7–10 days.
Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10%
Renal 60–80% as metabolites (glucuronide conjugates), biliary/fecal 10–20%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive